186 related articles for article (PubMed ID: 8162054)
21. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type I: overview.
St-Louis M; Tanguay RM
Hum Mutat; 1997; 9(4):291-9. PubMed ID: 9101289
[TBL] [Abstract][Full Text] [Related]
22. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.
Bergman AJ; van den Berg IE; Brink W; Poll-The BT; Ploos van Amstel JK; Berger R
Hum Mutat; 1998; 12(1):19-26. PubMed ID: 9633815
[TBL] [Abstract][Full Text] [Related]
23. Rapid nonradioactive assay for the detection of the common French Canadian tyrosinemia type I mutation.
Grompe M; al-Dhalimy M
Hum Mutat; 1995; 5(1):105. PubMed ID: 7728147
[No Abstract] [Full Text] [Related]
24. Tyrosine and its catabolites: from disease to cancer.
Tanguay RM; Jorquera R; Poudrier J; St-Louis M
Acta Biochim Pol; 1996; 43(1):209-16. PubMed ID: 8790725
[TBL] [Abstract][Full Text] [Related]
25. Purification of mRNA coding for the enzyme deficient in hereditary tyrosinemia, fumarylacetoacetate hydrolase.
Nicole LM; Valet JP; Laberge C; Tanguay RM
Biochem Cell Biol; 1986 May; 64(5):489-93. PubMed ID: 3718716
[TBL] [Abstract][Full Text] [Related]
26. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
27. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.
Phaneuf D; Labelle Y; Bérubé D; Arden K; Cavenee W; Gagné R; Tanguay RM
Am J Hum Genet; 1991 Mar; 48(3):525-35. PubMed ID: 1998338
[TBL] [Abstract][Full Text] [Related]
28. Enzyme defect in a case of tyrosinemia type I, acute form.
Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
[TBL] [Abstract][Full Text] [Related]
29. Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein.
Kvittingen EA; Rootwelt H; van Dam T; van Faassen H; Berger R
Pediatr Res; 1992 Jan; 31(1):43-6. PubMed ID: 1594329
[TBL] [Abstract][Full Text] [Related]
30. Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1.
Labelle Y; Puymirat J; Tanguay RM
Biochim Biophys Acta; 1993 Jan; 1180(3):250-6. PubMed ID: 8422430
[TBL] [Abstract][Full Text] [Related]
31. A nonsense mutation in the 4-hydroxyphenylpyruvic acid dioxygenase gene (Hpd) causes skipping of the constitutive exon and hypertyrosinemia in mouse strain III.
Endo F; Awata H; Katoh H; Matsuda I
Genomics; 1995 Jan; 25(1):164-9. PubMed ID: 7774914
[TBL] [Abstract][Full Text] [Related]
32. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation.
St-Louis M; Poudrier J; Tanguay RM
Hum Mutat; 1996; 7(4):379-80. PubMed ID: 8723698
[No Abstract] [Full Text] [Related]
33. Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.
Rootwelt H; Brodtkorb E; Kvittingen EA
Am J Hum Genet; 1994 Dec; 55(6):1122-7. PubMed ID: 7977370
[TBL] [Abstract][Full Text] [Related]
34. Deficiency of fumarylacetoacetase without hereditary tyrosinemia.
Kvittingen EA; Børresen AL; Stokke O; van der Hagen CB; Lie SO
Clin Genet; 1985 Jun; 27(6):550-4. PubMed ID: 4017276
[TBL] [Abstract][Full Text] [Related]
35. Identification of a combined missense/splice-site mutation in FAH causing tyrosinemia type 1.
Haghighi-Kakhki H; Rezazadeh J; Ahmadi-Shadmehri A
J Pediatr Endocrinol Metab; 2014 Jul; 27(7-8):795-8. PubMed ID: 24756054
[TBL] [Abstract][Full Text] [Related]
36. Correction of fumarylacetoacetate hydrolase deficiency (type I tyrosinemia) in cultured human fibroblasts by retroviral-mediated gene transfer.
Phaneuf D; Hadchouel M; Tanguay RM; Bréchot C; Ferry N
Biochem Biophys Res Commun; 1995 Mar; 208(3):957-63. PubMed ID: 7702626
[TBL] [Abstract][Full Text] [Related]
37. Hereditary tyrosinemia type I: strong association with haplotype 6 in French Canadians permits simple carrier detection and prenatal diagnosis.
Demers SI; Phaneuf D; Tanguay RM
Am J Hum Genet; 1994 Aug; 55(2):327-33. PubMed ID: 7913582
[TBL] [Abstract][Full Text] [Related]
38. Cytoplasmic nonsense-mediated mRNA decay for a nonsense (W262X) transcript of the gene responsible for hereditary tyrosinemia, fumarylacetoacetate hydrolase.
Dreumont N; Maresca A; Khandjian EW; Baklouti F; Tanguay RM
Biochem Biophys Res Commun; 2004 Nov; 324(1):186-92. PubMed ID: 15465000
[TBL] [Abstract][Full Text] [Related]
39. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway.
Endo F; Kubo S; Awata H; Kiwaki K; Katoh H; Kanegae Y; Saito I; Miyazaki J; Yamamoto T; Jakobs C; Hattori S; Matsuda I
J Biol Chem; 1997 Sep; 272(39):24426-32. PubMed ID: 9305902
[TBL] [Abstract][Full Text] [Related]
40. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.
Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M
Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
